Total Payments
$73,341
2024 Payments
$170.22
Companies
12
Transactions
145
Medicare Patients
489
Medicare Billing
$39,337
Payment Breakdown by Category
Consulting$37,979 (51.8%)
Travel$14,505 (19.8%)
Other$11,350 (15.5%)
Research$5,319 (7.3%)
Food & Beverage$3,883 (5.3%)
Education$304.57 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $37,979 | 8 | 51.8% |
| Travel and Lodging | $14,505 | 21 | 19.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $11,350 | 5 | 15.5% |
| Unspecified | $5,319 | 16 | 7.3% |
| Food and Beverage | $3,883 | 91 | 5.3% |
| Education | $304.57 | 4 | 0.4% |
Payments by Type
General
$68,022
129 transactions
Research
$5,319
16 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $30,342 | 66 | $0 (2023) |
| EMD Serono, Inc. | $14,661 | 21 | $0 (2019) |
| Acorda Therapeutics, Inc | $11,544 | 10 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $9,222 | 13 | $0 (2020) |
| Alexion Pharmaceuticals, Inc. | $5,794 | 7 | $0 (2019) |
| Biogen, Inc. | $913.22 | 16 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $325.49 | 3 | $0 (2017) |
| Genentech USA, Inc. | $220.30 | 3 | $0 (2024) |
| Alkermes, Inc. | $150.00 | 1 | $0 (2017) |
| SANOFI-AVENTIS U.S. LLC | $111.74 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $170.22 | 3 | Genentech USA, Inc. ($84.35) |
| 2023 | $121.66 | 4 | GENZYME CORPORATION ($65.85) |
| 2022 | $295.27 | 8 | GENZYME CORPORATION ($171.14) |
| 2021 | $111.74 | 2 | SANOFI-AVENTIS U.S. LLC ($111.74) |
| 2020 | $1,891 | 2 | Novartis Pharmaceuticals Corporation ($1,862) |
| 2019 | $16,140 | 43 | EMD Serono, Inc. ($7,402) |
| 2018 | $33,260 | 35 | GENZYME CORPORATION ($20,358) |
| 2017 | $21,351 | 48 | GENZYME CORPORATION ($7,349) |
All Payment Transactions
145 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/30/2024 | Biogen, Inc. | TYSABRI (Biological) | Education | In-kind items and services | $65.48 | General |
| Category: Neurology | ||||||
| 02/24/2024 | Genentech USA, Inc. | Ocrevus (Biological) | Food and Beverage | In-kind items and services | $84.35 | General |
| Category: Immunology | ||||||
| 02/24/2024 | Genentech, Inc. | Ocrevus (Biological) | Food and Beverage | In-kind items and services | $20.39 | General |
| Category: Immunology | ||||||
| 07/28/2023 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $21.17 | General |
| Category: Immunology | ||||||
| 05/04/2023 | GENZYME CORPORATION | AUBAGIO (Drug) | Education | In-kind items and services | $65.85 | General |
| Category: Neurology | ||||||
| 05/03/2023 | Genentech USA, Inc. | Enspryng (Biological), Ocrevus | Food and Beverage | In-kind items and services | $18.70 | General |
| Category: Immunology | ||||||
| 01/27/2023 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $15.94 | General |
| Category: Immunology | ||||||
| 10/25/2022 | Biogen, Inc. | VUMERITY (Drug) | Food and Beverage | In-kind items and services | $13.95 | General |
| Category: Neurology | ||||||
| 09/09/2022 | GENZYME CORPORATION | AUBAGIO (Drug) | Food and Beverage | In-kind items and services | $22.28 | General |
| Category: Neurology | ||||||
| 08/11/2022 | GENZYME CORPORATION | AUBAGIO (Drug) | Food and Beverage | In-kind items and services | $8.26 | General |
| Category: Neurology | ||||||
| 07/01/2022 | GENZYME CORPORATION | AUBAGIO (Drug) | Food and Beverage | In-kind items and services | $20.55 | General |
| Category: Neurology | ||||||
| 07/01/2022 | GENZYME CORPORATION | AUBAGIO (Drug) | Food and Beverage | In-kind items and services | $10.29 | General |
| Category: Neurology | ||||||
| 06/15/2022 | GENZYME CORPORATION | AUBAGIO (Drug) | Food and Beverage | In-kind items and services | $17.16 | General |
| Category: Neurology | ||||||
| 04/05/2022 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $110.18 | General |
| Category: Neurology | ||||||
| 04/04/2022 | GENZYME CORPORATION | AUBAGIO (Drug) | Food and Beverage | In-kind items and services | $92.60 | General |
| Category: Neurology | ||||||
| 11/22/2021 | SANOFI-AVENTIS U.S. LLC | LEMTRADA (Biological), AUBAGIO | Food and Beverage | In-kind items and services | $100.00 | General |
| Category: Neurology | ||||||
| 08/23/2021 | SANOFI-AVENTIS U.S. LLC | AUBAGIO (Drug) | Food and Beverage | In-kind items and services | $11.74 | General |
| Category: Neurology | ||||||
| 12/02/2020 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $1,862.00 | General |
| 02/28/2020 | GENZYME CORPORATION | LEMTRADA (Biological) | Food and Beverage | In-kind items and services | $28.62 | General |
| Category: Neurology | ||||||
| 12/06/2019 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Drug) | Food and Beverage | In-kind items and services | $33.23 | General |
| Category: Immunology | ||||||
| 11/04/2019 | GENZYME CORPORATION | AUBAGIO (Drug), LEMTRADA | Food and Beverage | In-kind items and services | $9.15 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 08/13/2019 | GENZYME CORPORATION | AUBAGIO (Drug) | Food and Beverage | In-kind items and services | $6.85 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 08/13/2019 | GENZYME CORPORATION | LEMTRADA (Drug), AUBAGIO | Food and Beverage | In-kind items and services | $5.05 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 08/13/2019 | GENZYME CORPORATION | LEMTRADA (Drug) | Food and Beverage | In-kind items and services | $4.16 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 08/06/2019 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $15.99 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab extension study (CAMMS03409) | GENZYME CORPORATION | $1,543 | 5 |
| A Prospective Observational Cohort Study in Adult Patients With Relapsing Multiple Sclerosis to Assess Patient Safety During and After Lemtrada (alemtuzumab) Infusions of the First Treatment Course | GENZYME CORPORATION | $1,149 | 1 |
| A Prospective Observational Cohort Study in Adult Patients With Relapsing Multiple Sclerosis to Assess Patient Safety During and After LEMTRADA (alemtuzumab) Infusions of the First Treatment Course | GENZYME CORPORATION | $544.97 | 1 |
| A long-term follow up study for multiple sclerosis patients who have completed the alemtuzumab extension study | GENZYME CORPORATION | $484.43 | 3 |
| A Long-Term Follow-Up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS3409),Comparison of Alemtuzumab and Rebif? Efficacy in Multiple Sclerosis, Study T | GENZYME CORPORATION | $446.67 | 1 |
| An Extension Protocol for Multiple Scerlosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,Comparison of Alemtuzumab and Rebif? Efficacy in Multiple Sclerosis, Study One (CARE | GENZYME CORPORATION | $446.67 | 1 |
| A prospective observational cohort study in patients with relapsing multiple sclerosis to assess patient safety during and after LEMTRADA (alemtuzumab) infusions of the first treatment course | GENZYME CORPORATION | $352.63 | 1 |
| A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409) | GENZYME CORPORATION | $179.26 | 2 |
| An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab | GENZYME CORPORATION | $172.47 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 92 | 109 | $40,775 | $8,341 |
| 2022 | 2 | 113 | 131 | $47,818 | $9,247 |
| 2021 | 3 | 132 | 154 | $39,629 | $12,347 |
| 2020 | 4 | 152 | 172 | $24,076 | $9,401 |
Total Patients
489
Total Services
566
Medicare Billing
$39,337
Procedure Codes
11
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 44 | 55 | $24,035 | $5,088 | 21.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 48 | 54 | $16,740 | $3,253 | 19.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 58 | 65 | $27,820 | $5,224 | 18.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 55 | 66 | $19,998 | $4,023 | 20.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 59 | 72 | $24,089 | $7,233 | 30.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 59 | 68 | $13,748 | $4,435 | 32.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 14 | 14 | $1,792 | $680.02 | 37.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 62 | 70 | $7,023 | $3,491 | 49.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 35 | 44 | $6,536 | $3,049 | 46.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 28 | 31 | $6,546 | $1,835 | 28.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 27 | 27 | $3,971 | $1,027 | 25.9% |
About Dr. Donna Graves, MD
Dr. Donna Graves, MD is a Neurology healthcare provider based in Charlotte, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/10/2007. The National Provider Identifier (NPI) number assigned to this provider is 1578766192.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Donna Graves, MD has received a total of $73,341 in payments from pharmaceutical and medical device companies, with $170.22 received in 2024. These payments were reported across 145 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($37,979).
As a Medicare-enrolled provider, Graves has provided services to 489 Medicare beneficiaries, totaling 566 services with total Medicare billing of $39,337. Data is available for 4 years (2020–2023), covering 11 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Charlotte, NC
- Active Since 06/10/2007
- Last Updated 07/15/2024
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1578766192
Products in Payments
- LEMTRADA (Drug) $29,894
- AMPYRA (Drug) $11,544
- Rebif (Biological) $6,863
- TYSABRI (Biological) $490.42
- Mavenclad (Biological) $453.53
- AUBAGIO (Drug) $430.40
- COPAXONE (Drug) $215.24
- MAYZENT (Drug) $133.35
- LEMTRADA (Biological) $128.62
- SPINRAZA (Biological) $122.54
- Ocrevus (Biological) $104.74
- BRIUMVI (Drug) $37.11
- SOLIRIS (Drug) $33.23
- GILENYA (Drug) $30.84
- Enspryng (Biological) $18.70
- TECFIDERA (Drug) $16.46
- VUMERITY (Drug) $13.95
- ZINBRYTA (Biological) $6.77
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Charlotte
Jill Conway, Md, MD
Neurology — Payments: $1.5M
Neurology $1.5M
Sanjay Iyer, Md, MD
Neurology — Payments: $620,868
Neurology $620,868
Dr. Megan Donnelly, D.o, D.O
Neurology — Payments: $471,292
Neurology $471,292
Danielle Englert Doggett, Md, MD
Neurology — Payments: $224,230
Neurology $224,230
Ardith Courtney, Do, DO
Neurology — Payments: $215,565
Neurology $215,565
Mohammad Bolouri, Md, MD
Neurology — Payments: $184,450
Neurology $184,450